Ƶ

Oral Semaglutide Sheds Pounds; USPSTF Taking Obesity Comments; Plant Extract for T2D

— News and commentary from the endocrinology world

Ƶ MedicalToday
Endo Break over a computer rendering of a man with illustrated body organs.

Once-daily helped adults with overweight or obesity achieve 15.1% weight loss -- or 17.4% weight loss with full treatment adherence -- in the phase IIIa OASIS 1 trial, said Novo Nordisk. A 7-mg and 14-mg version of oral semaglutide is currently approved for type 2 diabetes under the name Rybelsus.

Falling in line with previous studies, a Bavarian study showed that a diagnosis of COVID-19 was tied to an in children. (JAMA)

The U.S. Preventive Services Task Force (USPSTF) is on its draft research plan for weight-loss interventions to prevent obesity-related morbidity and mortality in adults.

Midlife women with prediabetes -- a fasting glucose between 100 to 125 mg/dL -- had a during and after the menopause transition compared with women free of diabetes. (JAMA Network Open)

Totum 63, an investigational combination of five plant extracts, in people with prediabetes and early-stage untreated type 2 diabetes in the phase II/III REVERSE-IT trial, Valbiotis announced.

The weight-loss drug semaglutide (Wegovy) may , early trial results suggested. (Reuters)

An increasing number of workplaces are becoming more "." (New York Times)

Do soft contact lenses contain ? (The Hill)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.